Differential blood-based diagnosis between benign prostatic hyperplasia and prostate cancer: miRNA as source for biomarkers independent of PSA level, Gleason score, or TNM status

Leidinger P, Hart M, Backes C, Rheinheimer S, Keck B, Wullich B, Keller A, Meese E (2016)

Publication Type: Journal article

Publication year: 2016

Journal

Tumor Biology Karger / Springer Verlag (Germany)

Book Volume: 37

Pages Range: 10177-85

Journal Issue: 8

DOI: 10.1007/s13277-016-4883-7

Abstract

Since the benefit of prostate-specific antigen (PSA) screening remains controversial, new non-invasive biomarkers for prostate carcinoma (PCa) are still required. There is evidence that microRNAs (miRNAs) in whole peripheral blood can separate patients with localized prostate cancer from healthy individuals. However, the potential of blood-based miRNAs for the differential diagnosis of PCa and benign prostatic hyperplasia (BPH) has not been tested. We compared the miRNome from blood of PCa and BPH patients and further investigated the influence of the tumor volume, tumor-node-metastasis (TNM) classification, Gleason score, pretreatment risk status, and the pretreatment PSA value on the miRNA pattern. By microarray approach, we identified seven miRNAs that were significantly deregulated in PCa patients compared to BPH patients. Using quantitative real time PCR (qRT-PCR), we confirmed downregulation of hsa-miR-221* (now hsa-miR-221-5p) and hsa-miR-708* (now hsa-miR-708-3p) in PCa compared to BPH. Clinical parameters like PSA level, Gleason score, or TNM status seem to have only limited impact on the overall abundance of miRNAs in patients' blood, suggesting a no influence of these factors on the expression of deregulated miRNAs.

Authors with CRIS profile

Bastian Keck Medizinische Fakultät Bernd Wullich Lehrstuhl für Urologie

Involved external institutions

Universität des Saarlandes (UdS) DE Germany (DE)

How to cite

APA:

Leidinger, P., Hart, M., Backes, C., Rheinheimer, S., Keck, B., Wullich, B.,... Meese, E. (2016). Differential blood-based diagnosis between benign prostatic hyperplasia and prostate cancer: miRNA as source for biomarkers independent of PSA level, Gleason score, or TNM status. Tumor Biology, 37(8), 10177-85. https://doi.org/10.1007/s13277-016-4883-7

MLA:

Leidinger, Petra, et al. "Differential blood-based diagnosis between benign prostatic hyperplasia and prostate cancer: miRNA as source for biomarkers independent of PSA level, Gleason score, or TNM status." Tumor Biology 37.8 (2016): 10177-85.

BibTeX: Download